Form 4: Icahn School of Medicine at Mount Sinai Acquires Additional Renalytix Shares in Private Placement

Icahn School of Medicine at Mount Sinai acquired 9,360,374 Ordinary Shares of Renalytix plc as part of the second tranche of a private placement.

Summary

• On April 24, 2024, Icahn School of Medicine at Mount Sinai (ISMMS) acquired 9,360,374 Ordinary Shares of Renalytix plc in the second tranche of a private placement.
• The private placement was conducted pursuant to a Placing Agreement dated March 12, 2024, with Stifel Nicolaus Europe Limited.
• The first tranche of the private placement, consisting of 19,986,031 Ordinary Shares, closed on March 14, 2024.
• The second tranche, consisting of 26,815,841 Ordinary Shares, closed on April 24, 2024, after receiving the necessary shareholder approval.
• ISMMS purchased the shares for approximately $2.3 million, equivalent to 20 pence per Ordinary Share or about $0.25 per share based on a conversion rate of 1 GBP to $1.2498 on April 23, 2024.
• After the transaction, ISMMS directly holds 19,317,248 Ordinary Shares and indirectly holds 1,382,489 American Depositary Shares (ADS), with each ADS representing two Ordinary Shares.
• The Mount Sinai Hospital (MSH), Mount Sinai Hospitals Group, Inc. (MSHG), and Mount Sinai Health System, Inc. (MSHS) may be deemed to beneficially own the securities held by ISMMS and MSH, but they disclaim beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a major institution increased its investment in the company, suggesting confidence in its future prospects. However, it's a routine transaction related to a previously announced private placement.

Positives

• Icahn School of Medicine at Mount Sinai increased its stake in Renalytix plc, demonstrating confidence in the company.
• The private placement provides Renalytix plc with additional capital to fund its operations and growth initiatives.

Industry Context

Private placements are a common method for companies, especially in the biotech and healthcare sectors, to raise capital from institutional investors. This investment indicates continued institutional interest in Renalytix's prospects.

Comparison to Industry Standards

• Private placements are frequently used in the biotech industry to fund research and development, clinical trials, and commercialization efforts.
• Similar companies, such as those developing diagnostic tests or medical devices, often rely on private placements to secure funding when traditional financing options are limited.
• The size of the placement and the involvement of a major institution like Icahn School of Medicine are typical for companies at Renalytix's stage of development.

Stakeholder Impact

• Shareholders may view the increased investment by Icahn School of Medicine positively.
• The capital raised through the private placement can support the company's growth and development, potentially benefiting employees and other stakeholders.

Key Dates